Corcept Therapeutics is rated Strong Buy with price targets of $163 in one year and $222 in two years, driven by rapid revenue and margin growth. The company’s new drug Lifyorli is launching quickly for platinum-resistant ovarian cancer, and Korlym continues steady growth, supporting over 44% revenue growth and nearly 98% gross margins. Upcoming catalysts include an FDA decision on Relacorilant for Cushing syndrome, potential European approvals, and important trial results. Corcept’s strong pipeline, cash reserves, and expanding salesforce position it well for future growth in major disease areas.
Tekcapital's portfolio company Guident has signed a 36-month agreement with Coastal Waste & Recycling to deploy its WatchBot autonomous inspection robots and AI software across more than 40 Coastal locations. The system will conduct facility patrols,...
Pop Mart's shares dropped more than 4% after it reported first-half revenue of 17.17 billion yuan, up 23.8% year-over-year but below expectations due to declines in Asia Pacific (excluding China) and the Americas. Revenue in China grew 47.3%, but sal...
Strategy holds 840,447 Bitcoin with an average acquisition cost of $75,385 per coin. On August 21, Bitcoin's price briefly climbed above this cost during an 8.5% daily rally, generating an estimated unrealized gain of about $192 million before prices...
Solana's price jumped nearly 20% last week, reaching $91 before settling near $89, driven by the US Treasury doubling bond buybacks to boost market liquidity. This policy shift sparked renewed investor confidence, leading to $14.58 million in net inf...
Bitcoin surged past $75,000 for the first time since May, driven by a crypto market rally following a White House event where President Trump urged Congress to pass the CLARITY Act, a crypto-friendly legislation. Ether and other major cryptocurrencie...
